No description available.

Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy characterized by inactivation of the von Hippel-Lindau tumour suppressor gene, the protein product of which mediates degradation of the transcription factor hypoxia-inducible factor (HIF). GAL3ST1 is a sulfotransferase which catalyzes the production of sulfatide, a plasma membrane sulfolipid previously implicated in metastasis. We observed GAL3ST1 overexpression in primary ccRCC tumours relative to matched-normal tissue and subsequently asked if GAL3ST1 was a HIF-responsive gene that facilitates ccRCC metastasis. GAL3ST1 expression was suppressed in ccRCC cells by stable reconstitution of wild-type VHL and also siRNA-mediated knockdown of HIF1alpha and HIF2alpha. Dual luciferase assays and chromatin immunoprecipitation revealed a hypoxia-response element in the GAL3ST1 5’-UTR that appeared to be crucial for HIF-mediated upregulation. Finally, stable knockdown of GAL3ST1 significantly impeded ccRCC cell invasion through an in vitro basement membrane mimic. These results suggest GAL3ST1 is a HIF-responsive gene that promotes tumour cell invasion.

Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy characterized by inactivation of the von Hippel-Lindau tumour suppressor gene, the protein product of which mediates degradation of the transcription factor hypoxia-inducible factor (HIF). GAL3ST1 is a sulfotransferase which catalyzes the production of sulfatide, a plasma membrane sulfolipid previously implicated in metastasis. We observed GAL3ST1 overexpression in primary ccRCC tumours relative to matched-normal tissue and subsequently asked if GAL3ST1 was a HIF-responsive gene that facilitates ccRCC metastasis. GAL3ST1 expression was suppressed in ccRCC cells by stable reconstitution of wild-type VHL and also siRNA-mediated knockdown of HIF1alpha and HIF2alpha. Dual luciferase assays and chromatin immunoprecipitation revealed a hypoxia-response element in the GAL3ST1 5’-UTR that appeared to be crucial for HIF-mediated upregulation. Finally, stable knockdown of GAL3ST1 significantly impeded ccRCC cell invasion through an in vitro basement membrane mimic. These results suggest GAL3ST1 is a HIF-responsive gene that promotes tumour cell invasion.

Many tumours contain regions of hypoxia which are difficult to treat by conventional radiotherapy. There is much interest in the ability of nitric oxide (^•NO) to radiosensitize hypoxic mammalian cells as a possible adjunct to radiotherapy but mechanisms for its action are unclear. It has been proposed that ^•NO may radiosensitize cells by ‘fixing’ radiation-induced DNA free radicals, and elevated radiation response by ^•NO in cells has been partly attributed to increased formation of DNA double strand breaks. In the work carried out for this thesis it is shown that reaction of ^•NO with radiation-induced nucleobase radicals produces some novel products. New pathways for the reactions of radiation-induced hydroxyl radicals with purine radicals are proposed. In addition, the effects of ^•NO on the yields of radiation-induced single strand breaks in anoxic plasmid DNA, and on anoxic mammalian cell radiosensitivity are investigated. Kinetics of formation and repair of radiation-induced double strand breaks indicate different effects of ^•NO on radiation-induced clustered and non-clustered DNA damage involving replication-induced DNA breaks. As ^•NO is an inhibitor of ribonucleotide reductase, some of the radiosensitizing properties of ^•NO may be due to reduction in the availability of 2-deoxyribonucleotides. Through studying reactions of ^•NO with tyrosine radicals, essential components of ribonucleotide reductase, this work has enhanced understanding into how ^•NO may inhibit the enzyme, which may offer new insights into the development of ^•NO-releasing anti-cancer agents. The potential for delivery of ^•NO to hypoxic tissue for radiotherapy has also been investigated in this work, through the development of bioreductively-activated pro-drugs. These novel agents are stable until reduced by one-electron reductants, when a ^•NO-releasing pro-drug is rapidly evolved, only in those regions which are sufficiently hypoxic. By increasing our understanding into the mechanisms involved in the ability of ^•NO to radiosensitize hypoxic cells, especially the reactivity of ^•NO with DNA radicals, knowledge has been gained into the identification, development and repair of radiation-induced DNA damage in cells, including clustered damage, in the presence of ^•NO. These studies contribute to further development of novel anti-cancer therapies based upon the release of ^•NO in hypoxic cells.

Purpose: Tumour hypoxia is the result of uncontrolled growth of the tumour and its vasculature and is often found in solid tumours. It has been known for some time that tumour hypoxia is associated with increased radio resistance and poorer treatment outcomes. While there are several techniques to image the tumour’s oxygenation, no metric or guideline exists that helps in automatically delineating those hypoxic cells into target volumes. Even though several hypoxic biomarkers have been developed and tested to detect visualise and localise hypoxic areas, most of these delineated areas show volumes that are not immediately suitable for dose planning (i.e. a speckled hypoxia distribution). This work deals with 18 cases of tumour hypoxia in patients with non-small cell lung cancer (NSCLC) and presents a method that gives guidance on how to construct hypoxic target volumes feasible for dose planning. Materials and Methods: PET-CT scans have been taken with the hypoxic biomarker 18F-HX4. Hypoxic volumes have been extracted using a threshold of 10mmHg. A region growing algorithm was used to develop the HTV delineation method. Individually calculated doses based on the pO2-distribution within the hypoxic target volume have been used for the construction of dose plans with 24 fractions. Results: Treatment plans that boost the hypoxic target volume whilst sparing surrounding organs at risk were possible to construct for those tumours lying outside the mediastinum. Tumours which volumes were partially or fully overlapping with the mediastinum showed conflicts with delivering the dose necessary for a tumour control probability (TCP) of at least 95% and not exceeding the dose constraints set for the mediastinum.

Il existe une littérature abondante sur les mécanismes cellulaires de résistance à la chimiothérapie, décrivant notamment les pompes d’efflux, les modifications des cibles (comme les topoisomérases) ou les altérations de l’apoptose. Peu de publications s’intéressent aux mécanismes de chimiorésistance liée au microenvironnement tumoral. Les agents anticancéreux doivent traverser l’interstitium tumoral pour atteindre toutes les cellules (dont les cellules hypoxiques éloignées des vaisseaux sanguins) à des concentrations suffisantes pour être létales. Les modèles de culture cellulaire en couches multiples ont permis de montrer la faible pénétration des molécules de chimiothérapie. Les techniques d’immunohistochimie permettent une mesure quantitative de la distribution de ces molécules à partir des vaisseaux sanguins. Nous avons évalué la pénétration de plusieurs inhibiteurs de topoisomérases : topotécan, doxorubicine, mitoxantrone et banoxantrone. Nous avons comparé la distribution de ces molécules à travers des tissus sains et des tissus tumoraux, démontrant la pénétration limitée des molécules de chimiothérapie dans les tumeurs. Par contre, nous avons montré que la banoxantrone pénètre rapidement et de façon uniforme. Cette pro-drogue est convertit en AQ4 (un inhibiteur de topoisomérase II ressemblant à la mitoxantrone) en condition d’hypoxie. La mitoxantrone cible les cellules bien oxygénées et AQ4 cible les cellules hypoxiques. Cette combinaison de traitement aboutit à une distribution intratumorale complémentaire et à une amélioration de l’activité antitumorale. Ainsi, optimiser la pénétration des chimiothérapies et/ou cibler spécifiquement les cellules hypoxiques peut contourner la chimiorésistance liée au microenvironnement tumoral. / There is a vast literature about mechanisms that lead to drug resistance of individual cancer cells, including drug export pumps, changes in expression of targets (such as topoisomerases) or alterations in apoptosis. A smaller number of publications has drawn attention to causes of drug resistance that depend on the solid tumour microenvironment. Drugs must penetrate the extra-vascular space to reach all of the cancer cells (including cells far from blood vessels in hypoxic condition) in sufficient concentration to cause lethal toxicity. Model systems such as multilayered cell cultures provide direct evidence of poor drug penetration through tumour tissue. In vivo techniques using quantitative immunohistochemistry allow studying drug distribution as a function of distance from the nearest blood vessel. We have evaluated the penetration of several topoisomerase inhibitors: topotecan, doxorubicine, mitoxantrone and banoxantrone (AQ4N). We have compared the distribution of these drugs through normal and tumour tissue, demonstrating the limited perivascular distribution of conventional chemotherapies in tumour. We have also showed the rapid and uniform penetration of banoxantrone. This pro-drug is reduced to AQ4 (a topoisomérase II inhibitor of similar structure to mitoxantrone) under hypoxic condition. The targeting of mitoxantrone to oxygenated regions and AQ4 to hypoxic tumour regions resulted in effective drug exposure over the entire tumour and increased tumour growth delay compared with either drug alone. Improving drug penetration and/or targeting hypoxic tumour cells may overcome chemoresistance due to the tumour microenvironment.